Intellia 治療公司
DE ˙ DB ˙ US45826J1051
€13.00 ↑1.80 (16.07%)
2026-06-04
分享價格
SecurityDE:38I / Intellia Therapeutics, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership6,418,836 shares
Ownership 5.50%
State Street Corp ownership in 38I / Intellia Therapeutics, Inc.

2026-02-09 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,418,836 shares of Intellia Therapeutics, Inc. (DE:38I). This represents 5.5 percent ownership of the company. In their previous filing dated 2025-05-13 , State Street Corp had reported owning 4,510,261 shares, indicating an increase of 42.32 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-02-09 2026-02-09 13G 4,510,261 6,418,836 42.32 5.50 25.00
2025-05-13 2025-05-13 13G 4,735,861 4,510,261 -4.76 4.40 -16.82
2024-01-24 2024-01-24 13G/A 1,693,469 4,735,861 179.65 5.29 52.89
2020-02-13 2020-02-13 13G/A 2,314,430 1,693,469 -26.83 3.46 -34.72
2019-02-13 2019-02-13 13G 2,314,430 5.30

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 6,922,676 503,840 7.85 88,749 53.80 0.0031
2026-02-13 2025-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 6,418,836 1,447,967 29.13 57,705 -32.78 0.0019
2025-11-14 2025-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 4,970,869 931,584 23.06 85,847 126.58 0.0030
2025-08-14 2025-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 4,039,285 -470,976 -10.44 37,888 18.15 0.0014
2025-05-15 2025-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 4,510,261 -695,437 -13.36 32,068 -47.17 0.0013
2025-02-14 2024-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 5,205,698 62,164 1.21 60,698 -42.57 0.0024
2024-11-14 2024-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 5,143,534 780,754 17.90 105,700 8.25 0.0043
2024-08-14 2024-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 4,362,780 -235,042 -5.11 97,639 -22.81 0.0043
2024-05-15 2024-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 4,597,822 -138,039 -2.91 126,486 -12.40 0.0057
2024-02-14 2023-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 4,735,861 1,002,936 26.87 144,396 22.33 0.0070
2023-11-14 2023-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 3,732,925 240,134 6.88 118,035 -17.13 0.0065
2023-08-14 2023-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 3,492,791 -46,847 -1.32 142,436 7.97 0.0075
2023-05-15 2023-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 3,539,638 -215,106 -5.73 131,922 0.70 0.0074
2023-05-15 2022-12-31 13F/A-99 INTELLIA THERAPEUTICS COM 45826J105 3,754,744 1,067,025 39.70 131,003 -12.90 0.0077
2023-05-15 2022-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 3,754,744 1,067,025 131,003 0.0077
2022-11-15 2022-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 2,687,719 -456,092 -14.51 150,405 -7.57 0.0095
2022-08-15 2022-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 3,143,811 746,284 31.13 162,724 -6.60 0.0098
2022-05-16 2022-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 2,397,527 556,076 30.20 174,228 -19.98 0.0086
2022-02-14 2021-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 1,841,451 179,721 10.82 217,733 -2.33 0.0103
2021-11-15 2021-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 1,661,730 -116,612 -6.56 222,921 -22.58 0.0118
2021-08-16 2021-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 1,778,342 -50,297 -2.75 287,931 96.20 0.0152
2021-07-09 2021-03-31 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 1,828,639 -414,101 -18.46 146,757 20.29 0.0084
2021-05-17 2021-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 1,828,639 -414,101 146,757 0.0084
2021-02-16 2020-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 2,242,740 -815,858 -26.67 122,005 100.65 0.0075
2020-11-10 2020-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 3,058,598 739,310 31.88 60,805 24.73 0.0042
2020-08-14 2020-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 2,319,288 594,605 34.48 48,751 131.12 0.0035
2020-06-19 2020-03-31 13F/A-1 INTELLIA THERAPEUTICS COM 45826J105 1,724,683 31,214 1.84 21,093 -15.09 0.0018
2020-05-11 2020-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 1,724,683 31,214 21,093 1,852.3901
2020-02-06 2019-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 1,693,469 -132,848 -7.27 24,843 1.89 0.0017
2019-11-14 2019-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 1,826,317 -21,963 -1.19 24,381 -19.42 0.0018
2019-08-14 2019-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 1,848,280 70,445 3.96 30,256 -0.36 0.0023
2019-05-15 2019-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 1,777,835 -536,595 -23.18 30,365 -3.88 0.0024
2019-02-12 2018-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 2,314,430 247,333 11.97 31,592 -46.59 0.0029
2018-11-09 2018-09-30 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 2,067,097 -629,324 -23.34 59,155 -19.82 0.0045
2018-08-14 2018-06-30 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 2,696,421 1,154,809 74.91 73,774 126.90 0.0062
2018-05-15 2018-03-31 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 1,541,612 386,542 33.46 32,514 46.47 0.0028
2018-02-14 2017-12-31 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 1,155,070 965,685 509.91 22,199 371.52 0.0018
2017-11-14 2017-09-30 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 189,385 24,587 14.92 4,708 78.47 0.0004
2017-08-14 2017-06-30 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 164,798 56,363 51.98 2,638 72.76 0.0002
2017-05-15 2017-03-31 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 108,435 16,080 17.41 1,527 26.09 0.0001
2017-02-09 2016-12-31 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 92,355 -2,225 -2.35 1,211 -24.69 0.0001
2017-01-13 2016-09-30 13F/A-1 INTELLIA THERAPEUTICS Common equity shares 45826J105 94,580 23,706 33.45 1,608 6.28 0.0002
2016-11-14 2016-09-30 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 94,580 1,608
2016-08-12 2016-06-30 13F INTELLIA THERAPEUTICS Common equity shares 45826J105 70,874 70,874 1,513 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.